Bloomberg
Conway: Trump to Lead Drug Pricing Conversation
Jan.12 -- Kellyanne Conway, counselor to President-elect Donald Trump, discusses Trump's planned efforts to affect drug pricing as part of the repealing and replacing of Obamacare. She speaks with Bloomberg's Kevin Cirilli on "Bloomberg...
Bloomberg
Novartis CEO on Earnings, New Drug Approvals, Drug Prices, Generics
Jan.30 -- Vasant Narasimhan, chief executive officer at Novartis, discusses 4Q earnings, his plan for new drug approvals, how his business could be impacted by Brexit, pricing pressure in the U.S., the generics business and their Roche...
Bloomberg
'PAWZ' Kills the ETF Industry With Cuteness
Jan.30 -- The ETF industry has something for everyone -- the ProShares Pet Care ETF (ticker: PAWZ) tracks companies tied to the pet-care industry. In this week's "There's an ETF for That," Bloomberg's Scarlet Fu breaks down the ins and...
Bloomberg
Moderna Sharing Less Data Since IPO, CEO Says
May.13 -- Moderna Inc. Chief Executive Officer Stephane Bancel discusses the biotech firm's recent initial public offering and pharmaceuticals development path on "Bloomberg Technology."
Bloomberg
Sanofi Sees Price Pressure for Diabetes Treatment
Oct. 28 -- Bloomberg's Sam Fazeli reports earnings from Sanofi, and outlook for both CEO changes and diabetes drugs. He speaks on Bloomberg Televisions ""Countdown."" (Source: Bloomberg)
Bloomberg
The Tax Inversion Deal Crackdown
Sept. 25 -- Bloomberg Intelligence Senior Pharmaceutical Analyst Sam Fazeli discusses tax inversion on Bloomberg Surveillance. (Source: Bloomberg)
Bloomberg
Japan's Current Recession May Delay Abes Tax Hike
Nov. 17 -- Bloomberg's Erik Schatzker reports on today's ""Top Headlines."" He speaks on Bloomberg Television's ""Market Makers."" (Source: Bloomberg)
Bloomberg
Thermo Fischer to Buy Patheon in $7.2 Billion Deal
May.15 -- Thermo Fischer Scientific Inc. reached an agreement to purchase Patheon NV in a deal worth $7.2 billion, including $2 billion in debt. Bloomberg's Alix Steel reports on "Bloomberg Daybreak: Americas."
Bloomberg
2016: Biotech’s Tumultuous Year
Dec.30 -- Bloomberg’s Doni Bloomfield discusses his 2017 outlook for the biotech sector on “Bloomberg Markets.â€
Bloomberg
U.S. Prosecutors Bear Down on Generic-Drug Companies
Nov. 3 -- U.S. prosecutors are bearing down on generic pharmaceutical companies in a sweeping criminal investigation into suspected price collusion, a fresh challenge for an industry that’s already reeling from public outrage over the...
Bloomberg
Novartis' CEO Sees Very Strong Pipeline for Future
Oct.24 -- Joe Jimenez, chief executive officer at Novartis, discusses third-quarter earnings, their strategic review of Alcon, shareholder value of Alcon and U.S. generic pricing. He speaks on "Bloomberg Daybreak: Europe."
Bloomberg
Guangzhou Pharma Reveals Grand Plan
Nov.22 -- China aims to make the Greater Bay Area the country’s leading hub of life sciences. Guangzhou Pharmaceutical Group is ready to cash in on this huge state-backed drive. In an exclusive interview with Bloomberg’s Tom Mackenzie,...
Bloomberg
Roche CEO Schwan on Profit Forecast, Drug Pipeline
Jul.27 -- Severin Schwan, chief executive officer at Roche Holding AG, discusses first-half results as the company raised its profit forecast for the year. He speaks with Bloomberg's Francine Lacqua on "Bloomberg Surveillance."
Bloomberg
ETFs of 'New Economies' Focusing on Disruptive Companies Favored: CLS
Sep.11 -- Shana Sissel, senior portfolio manager at CLS Investments, shares her investment strategy for exchange traded funds. She speaks with Shery Ahn and Paul Allen on "Bloomberg Daybreak: Australia."
Bloomberg
J&J Draws U.S. DOJ Probe on Talcum Powder Asbestos Denials
Jul.12 -- The U.S. Justice department is reportedly pursuing a criminal investigation into whether Johnson & Johnson lied to the public about the possible cancer risks of its talcum powder products. Bloomberg Opinion columnist Max Nisen...
Bloomberg
Opioid Lawsuit Links Counties in Fight Against Big Pharma
Aug.03 -- Mike Papantonio, senior partner at Levin Papantonio, discusses a class-action lawsuit against pharmaceutical companies over the U.S. opioid crisis. He speaks with Bloomberg's Kevin Cirilli on "Bloomberg Markets: Balance of Power."
Bloomberg
Innovent CFO Sees a Lot of Opportunities in China's Health Market
Jan.17 -- Ronnie Ede, chief financial officer at Innovent, discusses what he has in the pipeline to stay competitive, what they're bringing to the market, profitability and the impact the U.S.-China trade war is having on his business....
Bloomberg
Novartis CEO Narasimhan on Growth Prospects, Pandemic Disruption
Jul.21 -- Novartis AG Chief Executive Officer Vasant Narasimhan discusses second-quarter earnings, efforts to find a Covid-19 vaccine, and growth prospects. He speaks on "Bloomberg Markets: European Open" after the Swiss drugmaker...
Bloomberg
Singapore 2Q GDP to Be 'Deeply Contractionary': Oxford Economics
Jun.02 -- Sung-Eun Jung, economist at Oxford Economics, looks at how the coronavirus outbreak is affecting Singapore and Indonesia. Singapore on Tuesday enters the first of three phases to ease partial lockdown measures that have been in...
Bloomberg
Bernstein Favors India's Cipla, Dr. Reddy's, Sun Pharma, Lupin
Dec.16 -- Nithya Balasubramanian, health-care analyst at Bernstein, discusses the prospects for Covid-19 vaccine approvals in India, and the outlook for the country's pharmaceutical industry. She speaks with Rishaad Salamat and Juliette...
Bloomberg
Halliburton, Baker Hughes Deal Resurrected
Nov. 17 -- Bloomberg's Jeff McCracken reports on M&A activity in both the oil and pharmaceutical sector. He speaks with Betty Liu on Bloomberg Television's In The Loop. (Source: Bloomberg)
Bloomberg
Waging War Against Expensive Medications
Dec. 3 -- Express Scripts Senior Vice President and Chief Medical Officer Steven Miller discusses the fight to keep medication costs down. He speaks on In The Loop. (Source: Bloomberg)
Bloomberg
Roche Third-Quarter Sales Rise on Sales of New Medicines
Oct. 16 -- Roche Holding said third-quarter sales rose 1.8 percent, boosted by sales of its newer cancer medicines. Bloomberg's Manus Cranny reports on ""Countdown."" (Source: Bloomberg)